Skip to content

US · GERN · BIOTECHNOLOGY

Geron Corporation (GERN) intrinsic value and stock valuation

$0.87as of 2026-11-21 · Mkt cap 949.45M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Geron Corporation DCF and intrinsic value

InvestorsCraft values GERN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GERN’s statements →

Geron Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Foster City, CA 94404 geron.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$183.9M+274.4% 5y CAGRd
20112025
Net income
-$-85.78M
20112025
Free cash flow
-$-111.09M
20112025
Total equity
$225.9M+1.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$183.9M$77M$240K$600K$1.39M
Operating income-$-53.84M-$-173.73M-$-193.94M-$-138.55M-$-114M
Net income-$-85.78M-$-174.57M-$-184.13M-$-141.9M-$-116.11M
EPSd-$-128.67K-$-270.22K-$-322.67K-$-372.66K-$-354.39K
Operating cash flow-$-111.04M-$-218.62M-$-167.74M-$-127.38M-$-95.56M
Capital expenditure-$-50K-$-680K-$-830K-$-430K-$-210K
Free cash flow-$-111.09M-$-219.3M-$-168.57M-$-127.81M-$-95.76M
Total assets$570.5M$593.8M$394.1M$190.6M$226M
Total debt$251.6M$121.7M$85.9M$55.8M$55M
Net debt$172.1M$42.7M$15.9M-$-1.09M$20.1M
Total equity$225.9M$280.3M$248M$80M$126.4M
Cash and short-term investments$359.8M$406.6M$333.7M$172.8M$183.7M
Income statement
20252024202320222021
Revenue$183.9M$77M$240K$600K$1.39M
Cost of revenue$4.75M$1.26M$0.00$0.00$0.00
Gross profit$179.1M$75.7M$240K$600K$1.39M
Research and development expenses$73.7M$103.7M$125.1M$95.5M$85.7M
Selling, general and administrative expenses$159.3M$145.7M$69.1M$43.6M$29.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$233M$249.5M$194.2M$139.2M$115.4M
Cost and expenses$237.7M$250.7M$194.2M$139.2M$115.4M
Interest income$18.1M$19.6M$18.2M$2.53M$530K
Interest expense$32.7M$18.5M$8.31M$6.88M$3.74M
Depreciation and amortization$1.2M$1.22M$1.03M$870K$780K
Ebitda-$-51.92M-$-154.85M-$-174.78M-$-134.15M-$-111.59M
Operating income-$-53.84M-$-173.73M-$-193.94M-$-138.55M-$-114M
Total other income/expenses, net-$-31.95M-$-840K$9.82M-$-3.35M-$-2.11M
Income before tax-$-85.78M-$-174.57M-$-184.13M-$-141.9M-$-116.11M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-85.78M-$-174.57M-$-184.13M-$-141.9M-$-116.11M
Weighted average shares outstanding$666.7M$646M$570.7M$380.8M$327.6M
Weighted average diluted shares outstanding$666.7M$646M$570.7M$380.8M$327.6M
Balance sheet
20252024202320222021
Cash and short-term investments$359.8M$406.6M$333.7M$172.8M$183.7M
Net receivables$39.2M$38.8M$1.66M$3.14M$1.76M
Inventory$0.00$38.7M$0.00$0.00$0.00
Total current assets$520.3M$491M$341.4M$180.3M$187.2M
Property, plant and equipment, net$880K$4.19M$4.73M$4.94M$5.38M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$41.3M$94.5M$43.3M$0.00$28.7M
Total non-current assets$50.3M$102.8M$52.7M$10.3M$38.8M
Total assets$570.5M$593.8M$394.1M$190.6M$226M
Accounts payable$11.3M$8.6M$6.16M$10.2M$6.69M
Short-term debt$19.5M$970K$47.8M$21.9M$900K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$111.5M$88.3M$108.1M$76.7M$45.5M
Long-term debt$233.1M$120.7M$38.1M$33.9M$54.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$233.1M$225.2M$38.1M$33.9M$54.1M
Capital lease obligations$2.44M$3.24M$3.96M$4.6M$5.17M
Total liabilities$344.7M$313.5M$146.1M$110.6M$99.6M
Common stock$640K$610K$550K$390K$320K
Retained earnings-$-1.86B-$-1.77B-$-1.6B-$-1.41B-$-1.27B
Accumulated other comprehensive income (loss)$270K$260K$180K-$-220K-$-170K
Total equity$225.9M$280.3M$248M$80M$126.4M
Total investments$321.7M$422.1M$307M$115.9M$177.5M
Total debt$251.6M$121.7M$85.9M$55.8M$55M
Net debt$172.1M$42.7M$15.9M-$-1.09M$20.1M
Cash flow statement
20252024202320222021
Net income-$-85.78M-$-174.57M-$-184.13M-$-141.9M-$-116.11M
Depreciation and amortization$1.2M$1.22M$1.03M$870K$780K
Stock-based compensation$90K$31.3M$19.4M$8M$8.08M
Change in working capital-$-68.54M-$-68.41M$6.06M$5.03M$10.5M
Accounts receivable-$-380K-$-36.89M$1.49M-$-1.38M-$-1.04M
Inventory-$-77.92M-$-37.97M$0.00$1.38M$1.04M
Accounts payable$2.66M$2.44M-$-4.03M$3.5M-$-230K
Net cash provided by operating activities-$-111.04M-$-218.62M-$-167.74M-$-127.38M-$-95.56M
Investments in property, plant and equipment-$-50K-$-680K-$-830K-$-430K-$-210K
Acquisitions, net$0.00$0.00$179.5M-$-1.23M$1.59M
Net cash used for investing activities$107.3M-$-106M-$-180.32M$62.1M$72M
Common stock issued$2.27M$140.7M$213.3M$69.9M$20.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.27M$334.4M$362M$87.3M$48.6M
Net change in cash-$-1.44M$9.74M$13.9M$22M$25M
Cash at end of period$79.4M$80.9M$71.1M$57.2M$35.2M
Operating cash flow-$-111.04M-$-218.62M-$-167.74M-$-127.38M-$-95.56M
Capital expenditure-$-50K-$-680K-$-830K-$-430K-$-210K
Free cash flow-$-111.09M-$-219.3M-$-168.57M-$-127.81M-$-95.76M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Geron Corporation

        Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

        CEO
        Harout Semerjian
        Employees
        258
        Beta
        0.60

        Explore

        Frequently asked questions

        What is the intrinsic value of Geron Corporation (GERN)?

        InvestorsCraft does not currently publish an intrinsic value for GERN. How the IC value is calculated.

        Is GERN undervalued?

        InvestorsCraft does not publish an undervaluation signal for GERN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.